

## DAFTAR PUSTAKA

- Alberts, B., Johnson, A., Lewis, J., Morgan, D., Raff, M., Roberts, K., & Walter, P. (2008). Cancer. In B. Alberts, A. Johnson, J. Lewis, D. Morgan, M. Raff, K. Roberts, & P. Walter, *Molecular Biology of The Cell* (pp. 1091 - 1175). Abingdon: Garland Science.
- Alfarouk, K. O., Stock, C. M., Taylor, S., Walsh, M., Muddathir, A. K., Verduzco, D., Rauch, C. (2015). Resistance to Cancer Chemotherapy : Failure in Drug Response from ADME to P-gp. *Cancer Cell Int*, 15:17.
- Ambudkar, S. V., Sarfaty, C. K., Sauna, Z. E., & Gottesman, M. M. (2003). P-glycoprotein: from genomics to mechanism. *Nature*, 7468-7485.
- American Cancer Society. (2015). Cancer Facts and Figures. *Atlanta, GA*, 2 - 67.
- Ameyaw, M.-M., Regateiro, F., Li, T., Liu, X., Tariq, M., Mobarek, A., & Thornton, N. (2001). MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. *Pharmacogenetics J*, 11:217-221.
- Amstrong, D. K., Axilbund, J. E., Bell, J. G., Bristow, R. E., & Chi, D. S. (2010). *Early Diagnosis and Treatment of Ovarian Cancer*. Philadelphia: Saunders Elsevier.
- Andrew Owen, C. G. (2004). Relationship between the C 3435 T and G 2677 T(A) polymorphisms in the ABCB1 gene and P-glycoprotein expression in human liver. *Br J Clin Pharmacol*, 59(3):365-370.
- Annese, V., Valvano, M., Palmieri, O., & Latiano, A. (1997). Genetic linkage study of familial mediterranean fever (FMF) to 16p13.3 and evidence for genetic heterogeneity in the Turkish population. *J. Med. Genet*, 573 - 578.
- Ashariati, A. (2008). Polymorphism C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancer with HER2/Neu expression. *Folia Medica Indonesiana*, 44:41-46.
- Asmino, Diponegoro, M., & Soendoko, R. (1985). Masalah Kanker di Indonesia. *Yayasan Kanker Wisnu Wardhana*.
- Aydos, S., Karadag, A., Ozkan, T., Altunok, B., Bunsuz, M., Heidargholizadeh, S., . . . Sunguroglu, A. (2015). Assocation of MDR1 C3435T and C1236T single nucleotide polymorphisms with male factor infertility. *Genet. Mol. Res.*, 14(2):6330-6339.
- Balram, C., Sharma, A., Sivathanan, C., & Lee, E. J. (2003). Frequency of C3435T single nucleotide MDR1 genetic polymorphism in an Asian population: phenotypic-genotypic correlates. *Br J Clin Pharmacol*, 56:78-83.
- Bergmann, T. K., Green, H., Andersen, C. B., Mirza, M. R., Herrstedt, J., Holund, B., . . . Peterson, C. (2011). Retrospective Study of The Impact of Pharmacogenetic Variants on Paclitaxel Toxicity and Survival in Patients with Ovarian Cancer. *Eur J Clin Pharmacol*, 67:693 - 700.
- Bergmann, T., Brasch-Andersen, C., Green, H., Mirza, M., Pedersen, R., Nielsen, F., . . . Brosen, K. (2011). Impact of CYP2C8\*3 on paclitaxel clearance : a population

- pharmacokinetic and pharmacogenetic study in 93 patients with ovarian cancer. *Pharmacogenomics J*, 11:113-120.
- Bo Gao, A. R. (2014). Paclitaxel sensitivity in relation to ABCB1 expression, efflux and single nucleotide polymorphisms in ovarian cancer. *Scientific Reports*, 1-9.
- Brinkmann, U., & Eichelbaum, M. (2001). Polymorphisms in the ABC drug transporter gene MDR1. *Pharmacogenomics J*, 1:59 - 64.
- Chen, Z., Shi, T., Zhang, L., Zhu, P., & Deng, M. (2015). Mammalian drug efflux transporters of the ATP binding cassette family in multidrug resistance : a review of the past decade. *Elsevier*, 153-164.
- Chowbay B., L. H. (2005). Meta-analysis of the influence of MDR1 C3435T polymorphism on digoxin pharmacokinetics and MDR1 gene expression. *Br J Clin Pharmacol*, 60:159-171.
- Chunqiao Tian, P. C. (2012). Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: a Gynecologic Oncology Group study. *Gynecol Oncol*, 124:575-581.
- Farghaly, S., Smiljanic, T., & Manestar, D. (2012). *Ovarian Cancer - Basic Science Perspective*. Rijeka: InTech.
- Ford, J., & Hait, W. (1990). Pharmacology of drugs that alter multidrug resistance in cancer. *Pharmacol Rev*, 155 - 199.
- Goff, B., & Muntz, H. (2005). Screening and Early Diagnosis of Ovarian Cancer. *Women's Health in Primary Care*, 8:262.
- Goff, B., Mandel, L., Descher, C., Urban, N., Gough, S., & Schurman, K. (2007). Development of an ovarian cancer symptom index : possibilities for early detection. *Cancer*, 221.
- Gottesman, M. M. (2002). Mechanisms of Cancer Drug Resistance. *Annual Reviews Medical*, 615-627.
- Gottesman, M., & Fung, K. (2009). A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function. *Biochim Biophys Acta*, 1794:860-871.
- Gottesman, M., & Pastan, I. (1993). Biochemistry of multidrug resistance mediated by the multidrug transporter. *Annu Rev Biochem*, 385 - 427.
- Gottesman, M., Fojo, T., & Bates, S. (2002). Multidrug resistance in cancer : role of ATP - dependent transporters. *Nat Rev Cancer*, 48 - 58.
- Green, A. E., & Sonoda, Y. (2016). Ovarian Cancer : Practice Essentials, Background, Pathophysiology. *Medscape Reference*, 1 - 13.
- Green, A. E., & Sonoda, Y. (2016). Ovarian Cancer Treatment and Management. *Medscape*, 1 - 3.
- Green, H., Soderkvist, P., Rosenberg, P., Horvarth, G., & Peterson, C. (2008). ABCB1 G1199A polymorphism and ovarian cancer response to paclitaxel. *Journal of Pharmaceutical Sciences*, 2045 - 2048.
- Green, H., Soderkvist, P., Rosenberg, P., Mirghani, R. A., Rymark, P., Lundqvist, A. E., & Peterson, C. (2008). Pharmacogenetic Studies of Paclitaxel in the Treatment of Ovarian Cancer. *Basic Clin Pharmacol Toxicol*, 104:130 - 137.

- Hattori, H., Suminoe, A., Wada, M., Koga, Y., Kohno, K., Okamura, J., . . . Matsuzaki, A. (2007). Regulatory polymorphisms of multidrug resistance 1 (MDR1) gene associated with the development of childhood acute lymphoblastic leukemia. *Leuk Res*, 31:1633-1640.
- Higgins, C. (1992). ABC transporters : from microorganism to man. *Annu Rev Cell Biol*, 67 - 113.
- Hoffmeyer, S., Burk, O., Von richter, O., Arnold, H., & Brockmoller, J. (2000). Functional polymorphisms of the human multidrug-resistance gene : multiple sequence variation and correlation of one allele with P-glycoprotein expression and activity in vivo. *Proc Natl Acad Sci USA*, 3473 - 3478.
- Hosking, L., Lumsden, S., Lewis, K., Yeo, A., McCarthy, L., Bansal, A., . . . Xu, C.-F. (2004). Detection of Genotyping Errors by Hardy-Weinberg Equilibrium Testing. *Eur J Hum Genet*, 12:395-399.
- Huang, Y. (2007). Pharmacogenetics and Genomics of Membrane Transporters in Cancer Chemotherapy. *Cancer Metastasis Rev*, 26:183 - 201.
- Humeny, A., Rodel, F., Rodel, C., Sauer, R., Fuzesi, L., Becker, C., & Efferth, T. (2003). MDR1 single nucleotide polymorphism C3435T in normal colorectal tissue and colorectal carcinomas detected by MALDI-TOF mass spectrometry. *Anticancer Res*, 23:2735-2740.
- Ieiri, I., Takane, H., & Otsubo, K. (2004). The MDR1 (ABCB1) Gene Polymorphism and Its Clinical Implications. *Clin Pharmacokinet*, 43(9):553 - 576.
- Imer, T., Schuler, U., Thiede, C., Schwartz, U., Kim RB, Gotthard, S., & Freund, D. (2002). MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. *Cancer Res*, 4955 - 4962.
- Isla D, S. C. (2004). Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. *Ann Oncol* , 15:1194-1203.
- Jamrozik, K., Balcerzak, E., Calka, K., Piaskowski, S., Urbanska, R., Salagacka, A., . . . Robak, T. (2009). Polymorphisms and haplotypes in the multidrug resistance 1 gene (MDR1/ABCB1) and risk of multiple myeloma. *Leuk Res*, 33:332-335.
- Jayson, G. C., Kohn, E. C., Kitchener, H. C., & Ledermann, J. A. (2014). Ovarian Cancer. *Lancet*, 1376-1388.
- Jelovac, D., & Armstrong, D. K. (2011). Recent Progress in the Diagnosis and Treatment of Ovarian Cancer. *Ca Cancer J Clin*, 61:183-203.
- Jemal, A., Bray, F., & Center, M. (2011). Global Cancer Statistics. *CA Cancer J Clin*, 61 - 69.
- Jhamb, N., & Lambrou, N. C. (2010). Epidemiology and Clinical Presentation of Ovarian Cancer. In R. Bristow, & D. Armstrong, *Early Diagnosis and Treatment of Ovarian Cancer* (pp. 1-15). Philadelphia: Saunders Elsevier.
- Johnatty, S. E., Beesley, J., Paul, J., Fereday, S., Spurdle, A. B., Webb, P. M., . . . Harnett, P. R. (2008). ABCB1 (MDR1) Polymorphisms and Progression-Free Survival among Women with Ovarian Cancer following Paclitaxel/Carboplatin Chemotherapy. *Clin Cancer Res*, 14(17):5594 - 5601.
- Juliano, R., & Ling, V. (1976). A surface glycoprotein modulating drug permeability in chinese hamster ovary cell mutants. *Biochim biophys Acta*, 152.

- Kamazawa, S., Kigawa, J., Kanamori, Y., Itamochi, H., Sato, S., Iba, T., & Terakawa, N. (2002). Multidrug Resistance gene-1 is a useful predictor of paclitaxel-based chemotherapy for patient with ovarian cancer. *Gynecol Oncol*, 171 - 176.
- Kementerian Kesehatan RI. (2015). *InfoDATIN Pusat Data dan Informasi Kementerian Kesehatan RI*. Jakarta: Kementerian Kesehatan RI Pusat Data dan Informasi.
- Kumar, V., Cotran, R. S., & Stanley, R. L. (2004). *Buku Ajar Patologi*. New York: Saunders Elsevier.
- Leitao Jr, M. M., Barakat, R. R., Stack, M. S., & Fishman, D. A. (2009). *Ovarian Cancer Treatment and Research*. New York: Springer.
- Lemeshow, S., & Lawanga, S. (1991). *Sample size determination in health studies : a practical manual*. Geneva: World Health Organization.
- M. M. Baekelandt, R. H. (2000). P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer. *Anticancer Res*, 20:1061–1067 .
- M. Tanabe, I. I. (2001). Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. *J. Pharmacol. Exp. Ther* 297, 1137–1143.
- Maccio, A., Madeddu, C., Massa, D., Mudu, M. C., Lusso, M. R., Gramignano, G., . . . Mantovani, G. (2005). Hemoglobin Levels Correlate with Interleukin-6 levels in Patients with Advanced Untreated Epithelial Ovarian Cancer : Role of Inflammation in Cancer-Related Anemia. *Am Soc Haematol*, 106:362 - 367.
- Marchetti, C., Pisano, C., Facchini, G., Bruni, G., Magazzino, F., & Losito, S. (2010). First line treatment of Advanced ovaria cancer : current research and perpectives. *Expert Rev Anticancer*, 47 - 60.
- Marzolini, C., Paus, E., Buclin, T., & Kim, R. (2004). Polymorphism in human MDR1 (P-glycoprotein) : recent advances and clinical relevance. *Clin Pharmacol Ther*, 13-33.
- Morgan, M., Boyd, J., Drapkin, R., & Seiden, M. V. (2013). Cancers Arising in the Ovary. In M. Morgan, J. Boyd, R. Drapkin, & M. V. Seiden, *Abeloff's Clinical Oncology* (pp. 1592-1613).
- Mutiara, R., Agustinus, B., Sitompul, C. B., Malik, A., Gatot, D., & Suyatna, F. D. (2005). Multidrug resistance gene 1 polymorphisms in pediatric patients with leukemia at a national referral hospital in Indonesia. *Asian Biomedicine*, 9:625-630.
- Nakajima, M., Fujiki, Y., Satoru, K., Kanaya, T., Nakamura, M., Maida, Y., . . . Yokoi, T. (2005). Pharmacokinetics of Paclitaxel in Ovarian Cancer Patients and Genetic Polymorphism of CYP2C8, CYP3A4, and MDR1. *J Clin Pharmacol*, 45:674-682.
- Osswald, E., Johne, A., Laschinski, G., Arjomand-Nahad, F., Malzahn, U., Kirchheiner, J., . . . Kopke, K. (2007). Association of MDR1 genotypes with susceptibility to colorectal cancer in older non-smokers. *Eur J Clin Pharmacol*, 63:9-16.
- Pawlik, A., Wrzesniewska, J., Fiedorowicz-Fabrycy, I., & Gawronska-Szklarz, B. (2004). The MDR1 3435 Polymorphism in patients with rheumatoid arthritis. *Int J Clin Pharmacol Ther*, 496 - 503.

- Ratih, O., Ekowati, R., & Antonius, Y. K. (2011). Prevalensi Tumor dan Beberapa Faktor yang Mempengaruhinya di Indonesia. *Badan Penelitian dan Pengembangan Kesehatan*, 190 - 204.
- Raungkaewmanee, S., Tangjitgamol, S., Manusirivithaya, S., Srijaipracharoen, S., & Thavaramara, T. (2012). Platelet to lymphocyte ratio as a prognostic factor for epithelial ovarian cancer. *J Gynecol Oncol*, 23(4):265-273.
- Robert, J. (1999 ). Multidrug resistance in oncology: diagnostic and therapeutic approaches. *European Journal of Clinical Investigation*, 29:536–545.
- Rochet, N. M., Markovic, S. N., & Porrata, L. F. (2012, January 16). The Role of Complete Blood Cell Count in Prognosis. *Oncol Hematol Rev*, 8(1):76-82.
- Ryerson, A., Ehemann, C., Burton, J., McCall, N., Blackman, D., & Subramanian, S. (2007). Symptoms, diagnoses, and time to key diagnostic procedures among older U.S. women with ovarian cancer. *Obstet Gynecol*, 1053.
- Sarfaty, C. K., Marple, A. H., Shinar, S., Kimchi, A. M., Scavo, D., Roma, M. I., . . . Gottesman, M. M. (2007). Ethnicity-related Polymorphisms and Haplotypes in The Human ABCB1 gene. *Pharmacogenomics J*, 8(1):29-39.
- Sauer, G., Kafka, A., Grundmann, R., Kreienberg, R., Zeillinger, R., & Deissler, H. (2002). Basal expression of multidrug resistance gene 1 (MDR-1) is associated with the TT genotype at the polymorphic site C3435T in mammary and ovarian carcinoma cell lines. *Can Let*, 185:79-85.
- Schaeffeler, E., Elchelbaum, M., Brinkmann, U., Penger, A., & Asante-Poku, S. (2001). Frequency of C3435T polymorphism of MDR1 gene in African People. *The Lancet*, 383-384.
- Sharon, J., Jonathan, B., Bo, G., Xiaoqing, C., Yi, L., & Matthew, L. (2013). ABCB1 (MDR1) Polymorphisms and Ovarian Cancer Progression and Survival : A comprehensive analysis from the ovarian cancer association consortium and the cancer genome atlas. *National Institute of Health*, 8 - 14.
- Sheng, X., Zhang, L., Tong, N., Luo, D., Wang, M., Xu, M., & Zhang, Z. (2012). MDR1 C3435T polymorphism and cancer risk : a meta-analysis based on 39 case-control studies. *Mol Biol Rep*, 12:1554-1567.
- Sheps, J. A., Ling, V., Scherrman, J. M., Boumendjel, A., Boutonnat, J., & Jacques, R. (2009). *ABC Transporter and Multidrug Resistance*. New Jersey: John Wiley & Sons.
- Shibuya, K., Mathers, C., Pinto, C. B., Lopez, A., & Murray, C. (2002). Global and Regional estimates of cancer mortality and incidence by site. *BMC Cancer*, 37 - 62.
- Siegel, R., Ma, J., Zou, Z., & Jemal, A. (2014). Cancer Statistics 2014. *CA Cancer J Clin*, 69.
- Siegel, R., Ward, E., Brawley, O., & Jemal, A. (2011). Cancer Statistics, 2011 : The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. *CA Cancer J Clin*, 61.
- Siegmund, M., Brinkmann, U., Schaeffeler, E., Weirich, G., Schwab, M., Eichelbaum, M., . . . Brauch, H. (2002). Association of P-glycoprotein transporter MDR1(C3435T)

- polymorphism with the susceptibility to renal epithelial tumors. *J Am Soc Nephrol*, 13:1847-1854.
- Tahara, T., Arisawa, T., Shibata, T., Hirata, I., & Nakano, H. (2007). Multidrug Resistance 1 Polymorphism is Associated with Reduced Risk of Gastric Cancer in The Japanese Population. *J Gastroenterol Hepatol*, 22:1678-1682.
- Tewari, K. S., & Monk, B. J. (2015). *The 21st Century Handbook of Clinical Ovarian Cancer*. London: Springer International Publishing.
- Turgut, S., Yaren, A., Kursunluoglu, R., & Turgut, G. (2007). MDR1 C3435T polymorphism in patients with breast cancer. *Arch Med Res*, 38:539-544.
- Wang, J., Wang, B., Bi, J., Li, K., & Di, J. (2012). MDR1 gene C3435T polymorphism and cancer risk : a meta-analysis of 34 case-control studies. *J Cancer Res Clin Oncol*, 138:979-989.
- Ween, M., Armstrong, M., Oehler, M., & Ricciardelli, C. (2015). The role of ABC transporters in Ovarian Cancer Progression and Chemoresistance. *Elsevier*, 220-256.
- Wigginton, J. E., Cutler, D. J., & Abecasis, G. R. (2005). A Note on Exact Tests of Hardy-Weinberg Equilibrium. *Am. J. Hum. Genet.*, 76:883 - 887.
- Yamaguchi, H., Hishinuma, T., Endo, N., Tsukamoto, H., Kishikawa, Y., Sato, M., . . . Okamaru, C. (2006). Genetic variation in ABCB1 influences paclitaxel pharmacokinetics in Japanese patients with ovarian cancer. *Int J Gynecol Cancer*, 16:979-985.
- Yu Q.Z., H. J. (2007). The relationship between the polymorphisms of gene XGP and MDR1 and the responsiveness of advanced non-small cell lung cancer to platinum-based chemotherapy. *Practical J Cancer* , 22 : 252-256.